- Home
- SCNI vs PRFX Comparison
SCNI vs PRFX Comparison
Compare SCNI & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNI | PRFX |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SCNI | PRFX |
|---|---|---|
| Price | $0.80 | $3.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.4K | ★ 958.4K |
| Earning Date | 03-27-2026 | 10-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,147,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.03 | ★ N/A |
| Revenue Growth | ★ 303.87 | N/A |
| 52 Week Low | $0.61 | $2.73 |
| 52 Week High | $6.18 | $27.35 |
Technical Indicators
Market Signals| Indicator | SCNI | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 87.26 |
| Support Level | $0.75 | $0.58 |
| Resistance Level | $0.86 | $3.60 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | -0.02 | 0.28 |
| Stochastic Oscillator | 13.87 | 80.50 |
Price Performance
Historical ComparisonAbout SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.